Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT02412306 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Amgen

Collaborators

[object Object]